ReviewUnited European gastroenterology journal2022
Inflammatory bowel disease cross-sectional imaging: What's new?
Review in United European gastroenterology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Visual theranostic oral nanozymes for IBD from principles to preclinical design.Bioactive materials · 2026Review
- Computed tomography enterography-based deep learning radiomics models of intestinal lesions and perienteric fat for predicting Crohn's disease activity: a multicenter cohort study.Quantitative imaging in medicine and surgery · 2026Article
- The Utility of Mesenteric T1 Mapping on MR Enterography in Crohn's Disease: A Preliminary Study.Diagnostics (Basel, Switzerland) · 2025Article
- Automatic measurement of mesenteric vascular and portal vein parameters via PE-NET in the diagnosis of Crohn's disease.Frontiers in medicine · 2025Article
- Validation of intestinal ultrasound scores in assessing endoscopic activity of colonic and small intestinal Crohn's disease in a southwest Chinese cohort: a retrospective cross-sectional study.Quantitative imaging in medicine and surgery · 2024Article
- Bright Luminal Sign on High b-Value Diffusion-Weighted Magnetic Resonance Enterography Imaging as a New Biomarker to Predict Fibrotic Strictures in Crohn's Disease Patients: A Retrospective Preliminary Study.Journal of imaging · 2024Article
- The Diagnosis of Intestinal Fibrosis in Crohn's Disease-Present and Future.International journal of molecular sciences · 2024Review
- Predicting Treatment Response in Inflammatory Bowel Diseases: Cross-Sectional Imaging Markers.Journal of clinical medicine · 2023Review
- How to Evaluate Fibrosis in IBD?Diagnostics (Basel, Switzerland) · 2023Review
- Changing paradigms in management of inflammatory bowel disease.United European gastroenterology journal · 2022Article
- Inflammatory bowel disease cross-sectional imaging: What's new?United European gastroenterology journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cross-sectional imaging-ultrasonography, computed tomography enterography, and magnetic resonance enterography-is a routine and indispensable tool for patients with Crohn's disease (CD) that helps to detect or monitor disease characteristics before, during, and after CD treatment. New emerging radiological technologies may have further clinical applications in the management of CD. In this review article, we focus on the latest developments in cross-sectional imaging in CD research, including its role in intra- and extra-luminal lesion detection, intestinal inflammation and fibrosis grading, therapeutic response assessment and outcome prediction, postoperative recurrence detection and prediction, and the gut-brain axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.